Impact of pharmacists ACCESs to clinical information on the quality and the continuity of care in poly-medicamented community patients: a randomised controlled trial
ISRCTN | ISRCTN74420611 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN74420611 |
Secondary identifying numbers | N/A |
- Submission date
- 16/04/2008
- Registration date
- 18/06/2008
- Last edited
- 18/06/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Lyne Lalonde
Scientific
Scientific
Resaerch Team in Primary Care
CSSS de Laval, Hôpital de la Cité-de-la-Santé
1755 René-Laennec, room D-S145
Laval
H7M 3L9
Canada
Phone | +1 450 668 1010 ext. 2743 |
---|---|
lyne.lalonde@umontreal.ca |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Diagnostic |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | |
Study acronym | ACCES |
Study objectives | Drug-related problems (DRP) are associated with an increased morbidity and mortality. In the primary care setting, the number of poly-medicamented patients is constantly increasing, resulting in an increased risk of DRP. Access to clinical information, such as laboratory results and health problems, should help the community pharmacist detect more DRPs. The detection of these DRPs, and better documented pharmacist's suggestions, can result in an increase of the acceptance rate by general practitioners. To our knowledge, there are few studies on the impact of access to clinical information on the detection of DRPs by community pharmacists. |
Ethics approval(s) | Ethics approval received from the local medical ethics committee (Centre de santé et de services sociaux [CSSS] de Laval Ethics Committee) on the 24th September 2007. |
Health condition(s) or problem(s) studied | Drug-related problems from multiple prescription drugs |
Intervention | All pharmacists in the area of Laval were invited to a three-hour workshop on the interpretation of laboratory results. They also have access to a consultation service with pharmacists currently working at the Family Medicine Clinic of CSSS de Laval. For all patients, the family doctor asked the community pharmacist to perform an analysis of the pharmacotherapy. To help the pharmacist analyse the drug profile, the intervention group received the following clinical information: 1. Most recent laboratory results: 1.1. Creatinine clearance 1.2. Potassium 1.3. Sodium 1.4. Lipid profile 1.5. Alanine aminotransferase (ALT) 1.6. Creatine kinase (CK) 1.7. Glycosylated haemoglobin (HbA1c) 1.8. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) 1.9. Complete blood count 1.10. Blood levels of certain drugs (phenytoin, digoxin, lithium) 2. Health problems 3. Drug profile as figured in the medical record The control group received usual care. The duration of follow-up was 8 weeks in both groups. |
Intervention type | Other |
Primary outcome measure | The following will be assessed after two months of follow-up: 1. Compare the mean number of DRP per patient identified by community pharmacists in both groups (intervention group and control group) 2. Compare the mean number of pharmacotherapy changes per patient between both groups (intervention group and control group) |
Secondary outcome measures | The following will be assessed after two months of follow-up: 1. Compare the proportion of patients in each group for whom at least one intervention was made by the community pharmacists 2. For each type of intervention, compare the proportion of interventions made by the community pharmacists in both groups 3. Compare the proportion of pharmaceutical opinions that resulted in a pharmacotherapy change in both groups 4. Describe and compare the type of contact made between community pharmacists and Family Medicine Clinics pharmacists in both groups |
Overall study start date | 01/10/2007 |
Completion date | 24/04/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 170 |
Key inclusion criteria | Family doctors or residents: 1. Practicing at the Family Medicine Clinic of CSSS de Laval 2. Agree to participate and sign the consent form Community pharmacists: 1. Practicing in one of the pharmacies in the area of Laval or surrounding areas 2. Have one or more patients eligible for the study 3. Agree to participate and sign the consent form Patients: 1. 18 years old or older, either sex 2. Have an appointment at the Family Medicine Clinic of CSSS de Laval between October 2007 and March 2008 3. Takes at least five chronic medications 4. Reports being a patient of one of the participating pharmacies 5. Agrees to participate and sign the consent form 6. Is considered eligible by his family doctor |
Key exclusion criteria | 1. Is not able to speak or read French 2. Is a patient of more than one community pharmacy 3. Is not able to give a informed consent |
Date of first enrolment | 01/10/2007 |
Date of final enrolment | 24/04/2008 |
Locations
Countries of recruitment
- Canada
Study participating centre
Resaerch Team in Primary Care
Laval
H7M 3L9
Canada
H7M 3L9
Canada
Sponsor information
Pfizer (Canada)
Industry
Industry
c/o Chideh Motallebi, PhD, MBA
Spécialiste régional médical et de la recherche Cardiovasculaire - QC
Pfizer Canada Inc. Division Médicale
17300, autoroute Transcanadienne
Kirkland
H9J 2M5
Canada
Phone | +1 450 466 3952 |
---|---|
Chideh.Motallebi@Pfizer.com | |
Website | http://www.pfizer.ca |
https://ror.org/059g90c15 |
Funders
Funder type
Industry
Pfizer (Canada)
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Pfizer Inc., Pfizer Consumer Healthcare, Davis, Charles Pfizer & Company, Warner-Lambert, King Pharmaceuticals, Wyeth Pharmaceuticals, Seagen
- Location
- United States of America
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |